Ultreia Capital assumes management of LODH life science investments

Ultreia Capital Ltd and Lombard Odier Darier Hentsch & Cie have announced a collaboration and asset management agreement covering the private equity investments of Lombard Odier Darier Hentsch & Cie in the field of life sciences. Ultreia will assume the management of the respective holdings, valued at approximately SFr 200m. Assets in question include the private equity portion of the LODH Immunology Fund, a portfolio of 39 investments in private biotech companies. Ultreia has commenced operations on 1 January 2003 and will, in addition to the management of Lombard Odier Darier Hentsch & Cie's private equity portfolio, develop new investment vehicles in the life sciences sector.

Ultreia's capital has been fully subscribed by Corporate Investment Management Affentranger Holding AG and by its staff members. Anton Affentranger will serve as chairman of the board of directors. Ultreia's key staff members include Barbara Zink, Herman Kempen, Markus Hofer, Nicolas Fulpius and Melita Sun, the current Lombard Odier Darier Hentsch & Cie Life Sciences Private Equity team. Contact details: Ultreia Capital Ltd, Affentranger Associates Ltd, Rue du Rhône 100, 1204 Geneva, Switzerland; Tel: +41 79 447 85 65 and +41 22 310 09 43, Email: im@affentrangerassociates.com

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH